Related Experiment Videos

HMR-3562. Aventis Pharma

Z Ma1, A S Florjancic

  • 1Infectious Disease Research, Abbott Laboratories, Abbott Park, IL 60064-3537, USA. zhenkun.ma@abbott.com

Current Opinion in Investigational Drugs (London, England : 2000)
|March 15, 2002
PubMed

Insights

Aventis Pharma is developing novel 2-fluoroketolides, HMR-3562 and HMR-3787, as potent antibacterial agents. These compounds show effectiveness against gram-positive bacteria and respiratory pathogens like Haemophilus influenzae.

Area of Science:

  • Pharmaceutical Science
  • Microbiology
  • Medicinal Chemistry

Background:

  • Antibiotic resistance necessitates the development of novel antibacterial agents.
  • Ketolides represent a promising class of antibiotics with a unique mechanism of action.
  • Gram-positive bacteria and respiratory pathogens pose significant public health challenges.

Purpose of the Study:

  • To investigate the antibacterial potential of novel 2-fluoroketolides, HMR-3562 and HMR-3787.
  • To evaluate the in vitro and in vivo efficacy of these compounds against key pathogens.

Main Methods:

  • Synthesis and characterization of 2-fluoroketolide compounds.
  • In vitro susceptibility testing against a panel of gram-positive bacteria and respiratory pathogens.
  • In vivo efficacy studies in relevant animal models.

Main Results:

  • HMR-3562 and HMR-3787 demonstrated significant in vitro potency against various gram-positive bacteria.
  • The compounds exhibited efficacy against respiratory tract pathogens, including Haemophilus influenzae.
  • In vivo studies confirmed the antibacterial activity of the investigated ketolides.

Conclusions:

  • Novel 2-fluoroketolides HMR-3562 and HMR-3787 show promise as potential antibacterial agents.
  • These compounds warrant further investigation for the treatment of bacterial infections, particularly those caused by gram-positive bacteria and Haemophilus influenzae.

Related Concept Videos